PT - JOURNAL ARTICLE AU - Jaiswal, Sarita Rani AU - Saifullah, Ashraf AU - Arunachalam, Jaganath AU - Lakhchaura, Rohit AU - Tailor, Dhanir AU - Mehta, Anupama AU - Bhagawati, Gitali AU - Aiyer, Hemamalini AU - Biswas, Subhrajit AU - Khamar, Bakulesh AU - Malhotra, Sanjay V. AU - Chakrabarti, Suparno TI - Augmenting vaccine efficacy against delta variant with ‘Mycobacterium-<em>w</em>’ mediated modulation of NK-ADCC and TLR-MYD88 pathways AID - 10.1101/2022.11.02.22281822 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.02.22281822 4099 - http://medrxiv.org/content/early/2022/11/05/2022.11.02.22281822.short 4100 - http://medrxiv.org/content/early/2022/11/05/2022.11.02.22281822.full AB - Mycobacterium-w (Mw), was shown to boost adaptive natural killer (ANK) cells and protect against COVID-19 during the first wave of the pandemic. As a follow-up of the trial, 50 healthcare workers (HCW) who had received Mw in September 2020 and subsequently received at least one dose of ChAdOx1 nCoV-19 vaccine (Mw+ChAdOx1 group) were monitored for symptomatic COVID-19, during a major outbreak with the delta variant of SARS-CoV-2 (April-June, 2021), along with 201 HCW receiving both doses of the vaccine without Mw (ChAdOx1 group). Despite 48% having received just a single dose of the vaccine in Mw+ChAdOx1 group, only 2 had mild COVID-19, compared to 36 infections in the ChAdOx1 group (HR-0.46, p=0.009). Transcriptomic studies revealed an enhanced adaptive NK cell-dependent ADCC in the Mw+ChAdOx1 group, along with downregulation of TLR2-MYD88 pathway and concomitant attenuation of downstream inflammatory pathways. This might have resulted in robust protection during the pandemic with the delta variant.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2020/10/028326Funding StatementIUSSF/VN-COVID/049/2020Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of DNSH gave approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available in Gene Expression Omnibus(GEO) NCBI database with restricted access